XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.3

Revenue (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2023						2022						2023						2022
Net product revenue			$	7,306.2					$	6,119.2					$	20,524.2					$	19,123.0
Collaboration and other revenue(1)			2,192.4						822.4						4,246.5						2,116.6
Revenue			$	9,498.6					$	6,941.6					$	24,770.7					$	21,239.6

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $31.3 million and $86.8 million during the three and nine months ended September 30, 2023, respectively, and $43.3 million and $130.9 million during the three and nine months ended September 30, 2022, respectively.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the three months ended September 30, 2023 and 2022:

			Three Months Ended September 30,
			2023												2022
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Diabetes:
Trulicity®			$	1,259.0		$	414.6		$	1,673.6					$	1,418.3		$	432.0		$	1,850.4
Mounjaro®			1,277.0			132.4			1,409.3						97.3			90.0			187.3
Jardiance(1)			415.9			284.8			700.8						350.9			222.4			573.3
Humalog® (2)			194.2			201.2			395.4						248.1			198.8			447.0
Humulin®			145.5			61.2			206.7						169.5			68.7			238.2
Basaglar® (3)			111.4			68.2			179.6						124.8			68.1			193.0
Baqsimi			3.8			9.3			13.1						35.2			7.8			43.0
Other diabetes			53.2			88.6			141.9						44.5			86.2			130.4
Total diabetes			3,460.0			1,260.3			4,720.4						2,488.6			1,174.0			3,662.6
Oncology:
Verzenio®			684.6			355.7			1,040.2						414.8			202.9			617.7
Cyramza®			88.0			136.1			224.1						87.5			144.6			232.1
Erbitux®			134.0			19.9			153.9						126.3			18.7			144.9
Alimta®			21.2			32.3			53.5						64.6			54.8			119.4
Other oncology			73.8			201.5			275.4						39.5			139.6			179.2
Total oncology			1,001.6			745.5			1,747.1						732.7			560.6			1,293.3
Immunology:
Taltz®			509.3			234.9			744.2						493.8			186.1			679.9
Olumiant® (4)			65.7			165.7			231.4						22.9			160.0			182.9
Other immunology			—			11.4			11.4						—			3.6			3.6
Total immunology			575.0			412.0			986.9						516.7			349.7			866.4
Neuroscience:
Zyprexa(5)			49.9			1,431.5			1,481.4						8.0			73.4			81.4
Emgality®			126.5			42.1			168.5						114.0			54.6			168.5
Other neuroscience			31.0			87.0			118.2						23.8			99.4			123.3
Total neuroscience			207.4			1,560.6			1,768.1						145.8			227.4			373.2
Other:
Forteo®			101.2			45.2			146.4						112.7			64.4			177.1
Cialis®			4.9			82.0			86.8						8.1			107.7			115.7
COVID-19 antibodies(6)			—			—			—						386.6			—			386.6
Other			18.0			24.8			42.9						30.9			35.7			66.6
Total other			124.1			152.0			276.1						538.3			207.8			746.0
Revenue			$	5,368.1		$	4,130.5		$	9,498.6					$	4,422.1		$	2,519.4		$	6,941.6

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar®.

(4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.

(5) Zyprexa revenue includes sale of rights for the olanzapine portfolio.

(6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.

The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product for the nine months ended September 30, 2023 and 2022:

			Nine Months Ended September 30,
			2023												2022
			U.S.			Outside U.S.			Total						U.S.			Outside U.S.			Total
Diabetes:
Trulicity			$	4,177.7		$	1,285.6		$	5,463.2					$	4,162.4		$	1,341.1		$	5,503.5
Mounjaro			2,729.1			228.4			2,957.5						109.9			93.3			203.2
Jardiance(1)			1,131.5			815.1			1,946.6						831.4			622.4			1,453.7
Humalog(2)			695.6			601.2			1,296.8						855.8			656.4			1,512.3
Humulin			488.6			175.4			664.0						562.3			223.1			785.4
Baqsimi			633.1			25.4			658.4						79.5			21.7			101.2
Basaglar(3)			329.7			213.4			543.1						339.9			218.8			558.7
Other diabetes			131.1			260.7			392.0						116.1			254.8			371.0
Total diabetes			10,316.4			3,605.2			13,921.6						7,057.3			3,431.6			10,489.0
Oncology:
Verzenio			1,734.2			983.7			2,717.9						1,100.5			575.1			1,675.6
Cyramza			303.6			417.5			721.1						259.3			434.3			693.6
Erbitux			398.3			48.0			446.3						361.0			47.4			408.3
Alimta			59.2			113.5			172.6						490.5			200.5			691.1
Other oncology			194.7			521.4			716.2						124.1			422.3			546.4
Total oncology			2,690.0			2,084.1			4,774.1						2,335.4			1,679.6			4,015.0
Immunology:
Taltz			1,293.8			681.2			1,975.0						1,212.6			561.6			1,774.2
Olumiant(4)			158.8			520.4			679.2						104.6			520.1			624.7
Other immunology			—			39.0			39.0						0.1			12.1			12.1
Total immunology			1,452.6			1,240.6			2,693.2						1,317.3			1,093.8			2,411.0
Neuroscience:
Zyprexa(5)			69.1			1,581.9			1,651.0						26.2			235.5			261.7
Emgality			354.0			138.2			492.2						330.8			144.4			475.2
Other neuroscience			89.7			282.9			372.6						87.0			337.0			424.0
Total neuroscience			512.8			2,003.0			2,515.8						444.0			716.9			1,160.9
Other:
Forteo			269.2			147.6			416.8						261.4			191.7			453.0
Cialis			21.6			281.1			302.7						25.8			454.7			480.4
COVID-19 antibodies(6)			—			—			—						1,970.9			14.7			1,985.5
Other			73.0			73.4			146.5						119.4			125.1			244.8
Total other			363.8			502.1			866.0						2,377.5			786.2			3,163.7
Revenue			$	15,335.6		$	9,435.0		$	24,770.7					$	13,531.5		$	7,708.1		$	21,239.6

Numbers may not add due to rounding.

(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.

(2) Humalog revenue includes insulin lispro.

(3) Basaglar revenue includes Rezvoglar.

(4) Olumiant revenue includes sales for baricitinib that were made pursuant to EUA or similar regulatory authorizations.

(5) Zyprexa revenue includes sale of rights for the olanzapine portfolio.

(6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.

The following table summarizes revenue by geographical area:

			Three Months Ended September 30,												Nine Months Ended September 30,
			2023						2022						2023						2022
Revenue(1):
U.S.			$	5,368.1					$	4,422.1					$	15,335.6					$	13,531.5
Europe			2,568.6						1,056.4						4,837.1						3,224.8
Japan			390.8						487.7						1,233.6						1,352.3
China			390.8						343.4						1,162.6						1,102.0
Other foreign countries			780.3						632.0						2,201.8						2,029.1
Revenue			$	9,498.6					$	6,941.6					$	24,770.7					$	21,239.6

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer or other party.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

			September 30, 2023						December 31, 2022
Contract liabilities			$	200.7					$	219.2

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration